Valneva (NASDAQ:VALN) Trading Down 0.8% – Time to Sell?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) fell 0.8% during mid-day trading on Monday . The stock traded as low as $9.78 and last traded at $9.96. 50,512 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 66,159 shares. The stock had previously closed at $10.04.

Wall Street Analysts Forecast Growth

VALN has been the topic of a number of research reports. Wall Street Zen upgraded Valneva to a “hold” rating in a research note on Saturday, September 6th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Valneva in a research report on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Valneva in a research report on Wednesday, October 8th. Guggenheim lowered their price objective on shares of Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, September 8th. Finally, Jefferies Financial Group set a $14.00 target price on shares of Valneva and gave the company a “buy” rating in a research report on Monday, August 25th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Valneva has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Price Performance

The firm has a market cap of $855.86 million, a PE ratio of -10.16 and a beta of 1.86. The firm’s fifty day simple moving average is $10.10 and its two-hundred day simple moving average is $7.76. The company has a quick ratio of 1.77, a current ratio of 2.27 and a debt-to-equity ratio of 0.66.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. As a group, research analysts expect that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Trading of Valneva

Several institutional investors have recently made changes to their positions in VALN. Marex Group plc purchased a new position in Valneva in the 2nd quarter worth approximately $64,000. GAMMA Investing LLC bought a new stake in shares of Valneva during the first quarter valued at approximately $94,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Valneva in the second quarter worth $8,240,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.